SGLT-2 inhibitors have been subject to scrutiny with regard to their viability as ketogenic agents not only for the management of T2DM [113] but also for other conditions, including obesity [68], kidney disease, and HF [62], MAFLD [40], and metabolic syndrome [114]. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.